Efficacy and safety of linvoseltamab 200 mg in patients with relapsed/refractory multiple myeloma (RRMM): analysis of the LINKER-MM1 study

被引：0

作者：

Dhodapkar, Madhav ^{[1
]}

Bumma, Naresh ^{[2
]}

Richter, Joshua ^{[3
]}

Lee, Hans ^{[4
]}

Hoffman, James ^{[5
]}

Suvannasankha, Attaya ^{[6
,7
]}

Lentzsch, Suzanne ^{[8
]}

Shah, Mansi ^{[9
]}

Zonder, Jeffrey ^{[10
]}

Baz, Rachid ^{[11
]}

Wu, Ka Lung ^{[12
]}

Pianko, Matthew ^{[13
]}

Silbermann, Rebecca ^{[14
]}

Min, Chang-Ki ^{[15
]}

Vekemans, Marie-Christiane Madeleine ^{[16
]}

Munder, Markus ^{[17
]}

Byun, Ja Min ^{[18
]}

Martinez Lopez, Joaquin ^{[19
]}

DeVeaux, Michelle ^{[20
]}

Lorenc, Karen Rodriguez ^{[20
]}

Kroog, Glenn ^{[20
]}

Houvras, Yariv ^{[20
]}

Jagannath, Sundar ^{[1
,21
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[2] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH USA

[3] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA

[5] Univ Miami Hlth Syst, Miami, FL USA

[6] Univ Indianapolis, Simon Canc Ctr, Indianapolis, IN USA

[7] Roudebush VAMC, Indianapolis, IN USA

[8] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[9] Columbia Univ, Med Ctr, New York, NY USA

[10] Karmanos Canc Inst, Detroit, MI USA

[11] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[12] ZNA Stuivenberg, Dept Hematol, Antwerp, Belgium

[13] Univ Michigan, Rogel Canc Ctr, Sch Med, Ann Arbor, MI USA

[14] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR USA

[15] Seoul St Marys Hosp, Seoul, South Korea

[16] Univ Catholique Louvain UCLouvain, Dept Internal Med, Brussels, Belgium

[17] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 3, Mainz, Germany

[18] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Coll Med, Seoul, South Korea

[19] Univ Complutense, Hosp Univ 12 octubre, CNIO, Madrid, Spain

[20] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[21] Mt Sinai Med Ctr, New York, NY USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-247

引用

页码：S172 / S172

页数：1

共 50 条

[31] Indirect Comparison of Linvoseltamab Versus Selinexor Plus Dexamethasone for Penta-Exposed Relapsed/Refractory Multiple Myeloma (RRMM)
Zonder, Jeffrey
Lee, Hans
Richter, Joshua
Bumma, Naresh
Zhou, Zheng-Yi
Garcia-Horton, Viviana
Fillbrunn, Mirko
Wang, Hongjue
Mattera, Matthew
Ma, Wenxin
Ma, Qiufei
Inocencio, Timothy
Xu, Yingxin
Bergrath, Evelien
Harnett, James
Roccia, Tito
Kroog, Glenn S.
Lorenc, Karen Rodriguez
Houvras, Yariv
Jagannath, Sundar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S267 - S267
[32] Safety and Efficacy of Bortezomib in Refractory/Relapsed Multiple Myeloma
Lalagianni, C. E.
Neokleous, N.
Vadikoliou, C.
Papalexandri, A.
Apostolou, C.
Saloum, R.
Anagnostopoulos, A.
Fassas, A.
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S26 - S26
[33] The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma
贾亚静
China Medical Abstracts(Internal Medicine), 2020, 37 (03) : 189 - 189
[34] Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
Alegre, Adrian
Vicuna, Isabel
Aguado, Beatriz
CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
[35] Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple myeloma (RRMM): a subgroup analysis from MagnetisMM-3
Raab, M. S.
Haenel, M.
Raje, N.
Leleu, X.
Lesokhin, A.
Mohty, M.
Nooka, A. K.
Leip, E.
Conte, U.
Viqueira, A.
Manier, S.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 80 - 81
[36] Efficacy and safety of elranatamab in patients with high-risk relapsed/refractory multiple myeloma (RRMM): A subgroup analysis from MagnetisMM-3
Larson, Sarah Marie
Bahlis, Nizar J.
Maisel, Christopher
Karlin, Lionel
Yanovsky, Asya Varshavsky
Leip, Eric
Sullivan, Sharon T.
Viqueira, Andrea
Touzeau, Cyrille
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[37] Safety and efficacy of standard of care (SOC) teclistamab (TEC) in patients with relapsed/refractory multiple myeloma (RRMM), a single center experience
Grajales-Cruz, Ariel
Khadka, Sushmita
Blue, Brandon
Hansen, Doris
Puglianini, Omar Castaneda
Freeman, Ciara
De Avila, Gabriel
Ochoa-Bayona, Leonel
Liu, Hien
Nishihori, Taiga
Locke, Frederick
Shain, Ken
Baz, Rachid
Alsina, Melissa
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S39 - S40
[38] Safety and efficacy of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM).
Berenson, James R.
Stampleman, Laura
Bessudo, Alberto
Rosen, Peter
Klein, Leonard M.
Woliver, Thomas B. S.
Flam, Marshall S.
Eshaghian, Shahrooz
Nassir, Youram
Swift, Regina A.
Vescio, Robert A.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[39] Exposure-Response Analyses of Various Efficacy and Safety Endpoints in Support of Registrational Dose Selection of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma
Milberg, Oleg
Chiu, Joannellyn
Hazra, Anasuya
Upadhyay, Sameer
Kroog, Glenn S.
Lorenc, Karen Rodriguez
Davis, John D.
Dicioccio, A. Thomas
Harnisch, Lutz O.
Chittenden, Jason
BLOOD, 2024, 144 : 7056 - 7057
[40] Efficacy and Safety of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) With High-Risk (HR) Features: a Subgroup Analysis From the Phase 1/2 MajesTEC-1 Study
Costa, Luciano J.
Bahlis, Nizar J.
Usmani, Saad Z.
van de Donk, Niels W. C. J.
Nooka, Ajay K.
Perrot, Aurore
Qi, Keqin
Hodin, Caroline
Uhlar, Clarissa
Zuppa, Athena
Chastain, Katherine
Doyle, Margaret
Maria-Victoria, Mateos
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S546 - S547

← 1 2 3 4 5 →